TSVT — 2Seventy Bio Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-33.76%
3mn/a
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-73.81%
50d MA-38.23%
200d MA-40.76%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-464.48%
Return on Equityn/a
Operating Margin-603.86%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of 2Seventy Bio EPS forecast chart

Profile Summary

2Seventy Bio, Inc. is a cell and gene therapy company. The Company is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. It is advancing multiple preclinical and clinical programs in oncology. The Company's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. It is developing bbT369 product candidate as a treatment for patients with B-NHL.

Directors

    Last Annual
    December 31st, 2020
    Last Interim
    September 30th, 2021
    Incorporated
    January 1st, 1970
    Public Since
    January 1st, 1970
    No. of Employees
    420
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    23,369,088
    Blurred out image of a map
    Address
    60 Binney Street, CAMBRIDGE, 02210
    Web
    Phone
    +1 3394999300
    Auditors
    Ernst & Young LLP

    TSVT Share Price Performance

    FAQ

    Or unlock with your email

    Or unlock with your email